glp-1 bone loss Type 2 diabetes: Semaglutide may help protect health AAOS | A new study

MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy

Mistake 6: Storing medication incorrectly Leaving reconstituted medication on the counter, storing it in the fridge door, or freezing it accidentally all compromise potency

Pricing for Willow is based on its published rates as of April 2026

Heres how you can adapt to ensure your supply chain isnt disrupted

Like any medication, GLP-1s can cause side effects, especially in the early stages of treatment

Those receiving orlistat experienced an average weight loss of 4.1 kg, and those receiving placebo lost 2.8 kg